We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
Yahoo FinanceApr 17 04:35 ET
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
ROCKVILLE, Md., April 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development
GlobeNewswireApr 10 08:05 ET
Express News | MaxCyte Signs Strategic Platform License With Be Biopharma; Terms Not Disclosed
Moomoo 24/7Apr 2 08:09 ET
MaxCyte Signs Strategic Platform License With Be Biopharma to Support the Development of Engineer...
Stockhouse Apr 2 08:05 ET
MaxCyte(MXCT.US) Director Sells US$22,025 in Common Stock
$MaxCyte(MXCT.US)$ Director Johnston John Joseph sold 5,000 shares of Common Stock on Mar 26, 2024 at an average price of $4.405 for a total value of $22,025.Source: Announcement What is statement of
moomoo NewsMar 28 17:14 ET
Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were slightly lower this morning, with the Dow futures falling by around 0.1% on Wednesday. Shares of Harrow, Inc. (NASDAQ:HROW) fell sharply in today's pre-market trading after p
BenzingaMar 20 05:32 ET
Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term
Yahoo FinanceMar 17 04:24 ET
MaxCyte, Inc. (LON:MXCT) Just Reported And Analysts Have Been Cutting Their Estimates
Yahoo FinanceMar 14 09:41 ET
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript
Yahoo FinanceMar 14 08:15 ET
Express News | Stephens & Co. Reiterates Overweight on MaxCyte, Maintains $11 Price Target
Moomoo 24/7Mar 13 12:02 ET
Earnings Call: MaxCyte Reports Steady Growth Amid Market Challenges
InvestingMar 13 11:26 ET
NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. B of A Sec
BenzingaMar 13 08:51 ET
11 Oversold Healthcare Stocks To Buy Right Now
Yahoo FinanceMar 13 08:17 ET
MaxCyte Is Maintained at Buy by BTIG
MaxCyte Is Maintained at Buy by BTIG
Dow JonesMar 13 08:13 ET
Express News | BTIG Maintains Buy on MaxCyte, Lowers Price Target to $8
Moomoo 24/7Mar 13 08:03 ET
MaxCyte Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/13/2024 81.82% BTIG $10 → $8 Maintains Buy 11/29/2023 59.09% Craig-Hallum → $7 Initiates Coverage On →
BenzingaMar 13 08:01 ET
Q4 2023 MaxCyte Inc Earnings Call
Yahoo FinanceMar 13 07:56 ET
MaxCyte Stock Target Cut at BTIG on Conservative 2024 Guidance
InvestingMar 13 06:52 ET
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday. Shares of The Beauty Health Company (NASDAQ:SKIN) rose sharply in today's pre-market tra
BenzingaMar 13 06:16 ET
Earnings Call Summary | MaxCyte(MXCT.US) Q4 2023 Earnings Conference
The following is a summary of the MaxCyte, Inc. (MXCT) Q4 2023 Earnings Call Transcript:Financial Performance:MaxCyte reported a full year revenue of $41.3 million in 2023, down 7% from 2022. However,
moomoo AIMar 12 22:57 ET · Conference Call
No Data
No Data